The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s total. For 2025, a mean of 21 deals have been made compared to the historical annual mean of 19, according to a recent analysis from Leerink Partners. The firm included data from 2009 to Oct. 9 of this year. Since then, several high-profile deals have been made. As of Oct. 9, $65 billion was recorded in deal flow so far this year—a figure that nearly doubles 2024’s entire annual total of $37 billion as M&A deals grow larger following a period of “conservatism and recovery,” the analysts found.
Read the full article: 2025 Biopharma M&A Up in Value and Deal Count after Year of ‘Conservatism and Recovery’: Leerink Partners //
Source: https://www.fiercebiotech.com/biotech/2025-ma-value-and-count-after-year-conservatism-and-recovery-leerink-partners